Literature DB >> 29611085

Paradoxical skin lesions induced by anti-TNF-α agents in SAPHO syndrome.

Chen Li1, Xia Wu2, Yihan Cao2, Yueping Zeng2, Weihong Zhang3, Shuo Zhang2, Yuehua Liu2, Hongzhong Jin2, Wen Zhang4, Li Li5.   

Abstract

The objectives of the study were to characterize the clinical picture of paradoxical skin lesions in SAPHO patients treated with anti-TNF-α agents and to explore its pathogenesis. Patients treated with anti-TNF-α therapy were identified from a cohort of 164 SAPHO patients. The clinical data and skin biopsies were collected. The usage, efficacy, and side effects of anti-TNF-α therapy were recorded. Forty-one (25.0%) patients received anti-TNF-α therapy, of which seven (17.1%) developed paradoxical skin lesions after 1 to 14 infusions. Patients with such lesions were older at onset of skin lesions than those without (p = 0.034). Expression of TNF-α in palmoplantar pustulosis increased after anti-TNF-α therapy in the two examined patients with exacerbated skin lesions. Anti-TNF-α therapy induces paradoxical skin lesions in 17.1% SAPHO patients. Late onset of skin manifestations is associated with an increased risk of such lesions. The paradoxical elevation of TNF-α expression in lesions may contribute to this phenomenon.

Entities:  

Keywords:  Age of onset; Palmoplantar pustulosis; Psoriasiform lesions; SAPHO syndrome; Side effects; Tumor necrosis factor-α inhibitor

Mesh:

Substances:

Year:  2018        PMID: 29611085     DOI: 10.1007/s10067-018-4083-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  39 in total

1.  SAPHO syndrome: a long-term follow-up study of 120 cases.

Authors:  G Hayem; A Bouchaud-Chabot; K Benali; S Roux; E Palazzo; O Silbermann-Hoffman; M F Kahn; O Meyer
Journal:  Semin Arthritis Rheum       Date:  1999-12       Impact factor: 5.532

2.  Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions.

Authors:  A F Edrees; S N Misra; N I Abdou
Journal:  Clin Exp Rheumatol       Date:  2005 Jul-Aug       Impact factor: 4.473

3.  Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.

Authors:  H-H Lee; I-H Song; M Friedrich; A Gauliard; J Detert; J Röwert; H Audring; S Kary; G-R Burmester; W Sterry; M Worm
Journal:  Br J Dermatol       Date:  2007-03       Impact factor: 9.302

4.  Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.

Authors:  P Charles; M J Elliott; D Davis; A Potter; J R Kalden; C Antoni; F C Breedveld; J S Smolen; G Eberl; K deWoody; M Feldmann; R N Maini
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

5.  In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations.

Authors:  A Massara; P L Cavazzini; F Trotta
Journal:  Rheumatology (Oxford)       Date:  2006-01-10       Impact factor: 7.580

6.  A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.

Authors:  M Dastmalchi; C Grundtman; H Alexanderson; C P Mavragani; H Einarsdottir; S Barbasso Helmers; K Elvin; M K Crow; I Nennesmo; I E Lundberg
Journal:  Ann Rheum Dis       Date:  2008-02-13       Impact factor: 19.103

Review 7.  The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review.

Authors:  Beni Grinblat; Morton Scheinberg
Journal:  Semin Arthritis Rheum       Date:  2007-07-20       Impact factor: 5.532

8.  Psoriasiform and pustular eruption induced by infliximab.

Authors:  Hidetoshi Takahashi; Yoshio Hashimoto; Akemi Ishida-Yamamoto; Toshifumi Ashida; Yutaka Kohgo; Hajime Iizuka
Journal:  J Dermatol       Date:  2007-07       Impact factor: 4.005

9.  SAPHO syndrome treated with pamidronate: an open-label study of 10 patients.

Authors:  H Amital; Y H Applbaum; S Aamar; N Daniel; A Rubinow
Journal:  Rheumatology (Oxford)       Date:  2004-02-24       Impact factor: 7.580

10.  Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.

Authors:  Marcel Flendrie; Wynand H P M Vissers; Marjonne C W Creemers; Elke M G J de Jong; Peter C M van de Kerkhof; Piet L C M van Riel
Journal:  Arthritis Res Ther       Date:  2005-04-04       Impact factor: 5.156

View more
  4 in total

Review 1.  New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations.

Authors:  Wei Cheng; Fen Li; Jing Tian; Xi Xie; Jin-Wei Chen; Xiao-Fei Peng; Qi Tang; Yan Ge
Journal:  J Inflamm Res       Date:  2022-04-13

2.  Demographic, clinical, and scintigraphic comparison of patients affected by palmoplantar pustulosis and severe acne: a retrospective study.

Authors:  Yueting Li; Chen Li; Nan Wu; Feng Li; Zhihong Wu; Xiaochuan Sun; Qiyi Li; Li Li
Journal:  Clin Rheumatol       Date:  2020-01-17       Impact factor: 2.980

3.  Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.

Authors:  Ben Li; Guan-Wu Li; Luan Xue; Yue-Ying Chen
Journal:  World J Clin Cases       Date:  2020-10-06       Impact factor: 1.337

4.  Successful treatment of synovitis, acne, pustulosis, hyperostosis, and osteitis and paradoxical skin lesions by Tripterygium wilfordii hook f: a case report.

Authors:  Xinlu Zhang; Xia Wu; Chen Li
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.